Anti-BCMA-CAR NK Cells Expressing Soluble TRAIL: Promising Therapeutic Approach for Multiple Myeloma in Combination with Bortezomib and γ-Secretase Inhibitors

Motais, Benjamin; Charvátová, Sandra; Hrdinka, Matouš; Hájek, Roman; Bagó, Juli R.

doi:10.1182/blood-2022-166167

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NK cells are cells of the innate immune response and thus besides reduced alloreactivity NK cells have another huge advantage as compared to T cells, they are able to exert cytotoxic effects without the recognition of specific antigens. At the moment NK cells are genetically engineered with various receptors, such as αCD38, 48 NKG2D, 49 or anti‐BCMA 50 and tested in preclinical models for the treatment of MM.…”

Section: Allogeneic Car T Cell Therapymentioning

confidence: 99%

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Fischer,

Grieb,

Platzbecker

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

The introduction of chimeric antigen receptor (CAR) T cells revolutionized treatment of relapsed and refractory multiple myeloma (RRMM) in recent years. Currently, two CAR T cell products—idecabtagene vicleucel and ciltacabtagene autoleucel—are approved in the United States and the European Union to treat patients with three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti‐CD38 antibody. Moreover, seminal phase III trials of both agents in earlier lines of therapy have been published recently. Despite unprecedented rates of deep and lasting remissions in RRMM, there are still areas of uncertainty regarding the optimal use and distribution of CAR T cells in multiple myeloma. In the current review, we discuss the available data on approved CAR T cell products as well as unmet clinical needs and ongoing developments to optimize usage of this promising treatment modality in multiple myeloma.

show abstract

Section: Allogeneic Car T Cell Therapymentioning

confidence: 99%

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Fischer,

Grieb,

Platzbecker

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

show abstract

“… 10 Similarly, anti-BCMA CAR-NK cells are being studied in pre-clinical phase in different models, with good results and may possess a place in the BCMA therapeutics shelf in the future. 112 , 113 …”

Section: Future Directionsmentioning

confidence: 99%

“…10 Similarly, anti-BCMA CAR-NK cells are being studied in preclinical phase in different models, with good results and may possess a place in the BCMA therapeutics shelf in the future. 112,113 Currently, BCMA directed therapies are only available for R/R MM patients, but many trials are underway to explore their role at earlier stages and in combination with other myeloma therapies and in patients with high-risk disease (Table 3).…”

Section: Future Directionsmentioning

confidence: 99%

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

Shrivastava¹,

Rhee²,

Hadidi³

2023

OTT

View full text Add to dashboard Cite

Relapsed/refractory multiple myeloma remains a challenging disease necessitating the development of more effective treatment options. In the past decade, myeloma therapies have made significant advancements with the introduction of new treatment modalities. One of the new major targets for these novel therapeutics has been B-cell maturation antigen (BCMA), which is expressed on mature B-lymphocytes and plasma cells. There are three main categories of BCMA-targeted therapies currently available, including bispecific antibodies (BsAbs), antibody drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies. In this review, we discuss the existing BCMA-targeted therapies and provide insights into currently available treatment and future developments, with a particular focus on clinical efficacy and common drug-related adverse events.

show abstract

Exploring cellular immunotherapy platforms in multiple myeloma

Vo,

Jung,

Nguyen

et al. 2024

Heliyon

View full text Add to dashboard Cite

Anti-BCMA-CAR NK Cells Expressing Soluble TRAIL: Promising Therapeutic Approach for Multiple Myeloma in Combination with Bortezomib and γ-Secretase Inhibitors

Cited by 6 publications

References 0 publications

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

Exploring cellular immunotherapy platforms in multiple myeloma

Contact Info

Product

Resources

About